MADRIGAL PHARMACEUTICALS, INC. Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature of $47.59 million for the 12-month period ending 2016-12-31, per its 10-K filed 2019-02-27.
Discontinued › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature · last filed 2019-02-27
- MADRIGAL PHARMACEUTICALS, INC. adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2016 was $47.59M.
| Period end | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 12 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 12 month as first filed |
|---|---|---|
| 2016-12-31 | $47.59M 10-K · filed 2019-02-27 | $47.59M 10-K · filed 2017-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |